Search Results - "Misura‐Jakobac, K."

PS1265 IMPROVEMENTS IN OUTCOME OF MANTLE‐CELL LYMPHOMA (MCL) ARE MOSTLY DUE TO ADVANCES IN INDUCTION THERAPY AND AUTOLOGOUS STEM‐CELL TRANSPLANTATION (ASCT) – A REAL‐LIFE NON‐INTERVENTIONAL STUDY OF KROHEM by Aurer, I., Misura‐Jakobac, K., Sincic‐Petricevic, J., Deak, D., Vodanovic, M., Jakic‐Bubalo, M., Mitrovic, Z., Grubesic, A., Dreta, B., Zupanic‐Krmek, D., Coha, B.

“…Background: Outcome of patients with newly diagnosed MCL has improved substantially in the last decade. This coincided with the more frequent use of high‐dose…”
Get full text

PB1907 IBRUTINIB THERAPY IS ASSOCIATED WITH SERIOUS INFECTIONS IN PATIENTS WITH B‐CELL MALIGNANCIES ‐ A SINGLE CENTER EXPERIENCE by Misura Jakobac, K., Milunovic, V., Kursar, M., Mandac Rogulj, I., Ostojic Kolonic, S., Radic‐Kristo, D.

“…Background: Ibrutinib is an irreversible inhibitor of Bruton tyrosine kinase (BTK). Recently, ibrutinib has become available in Croatia for chronic lymphocytic…”
Get full text